Correlation between Furin promoter methylation levels and blood pressure of non-diabetic population in a community

doi:10.11958/20251552

Abstract

Abstract:

Objective To investigate the correlation between Furin promoter methylation level and blood pressure in a community-based non-diabetic population. Methods A secondary analysis was conducted on the research data from a study in the Dryad open database regarding the methylation rate of Furin promoter and the risk of diabetes. After including the participants from the original data and excluding those with a history of cardiovascular disease, diabetes or diagnosed diabetes at the time of enrollment, those lacking blood samples, those who refused to participate in follow-up examinations, those who died during the follow-up period and those with missing data, a total of 1 832 subjects formed the community non-diabetic population. The methylation rates of 8 CpG sites in the Furin promoter region, fasting blood glucose, lipid and blood pressure were collected at baseline. The subjects were divided into the normal systolic blood pressure (SBP) group (1 388 cases) and the elevated SBP group (444 cases) based on whether SBP was ≥140 mmHg, the diastolic blood pressure (DBP) was ≥90 mmHg and the hypertension diagnostic criteria (SBP≥140 mmHg or DBP≥90 mmHg. There were 1 341 cases in the normal DBP group, 491 cases in the elevated DBP group and 1 218 cases in the normal blood pressure group. A multivariate linear regression model was used to observe the correlation between the methylation rate of the Furin promoter and changes of SBP and DBP. For the Furin promoter methylation sites independently related to SBP/DBP. Linear regression models adjusted for confounding factors were used to fit the curve to observe whether there was a non-linear relationship between SBP or DBP and the methylation rate of the Furin promoter, respectively. Unadjusted and adjusted Logistic regression models were used to observe the correlation between the methylation rate of the Furin promoter and the risk of hypertension. The adjustment factors in the adjusted Logistic regression model were identical to those in the linear regression fitting curve. Results Compared with the normal SBP group, the methylation rates of CpG1, CpG2 and CpG4 were decreased in the elevated SBP group, while the methylation rate of CpG8 was increased (P<0.05). Compared with the normal DBP group, the methylation rates of CpG2 and CpG4 were decreased in the elevated DBP group, while the methylation rate of CpG8 was increased (P<0.01). Compared with the normal blood pressure group, the methylation rates of CpG1, CpG2, CpG4 and CpG6 were decreased in the hypertension group, while the methylation rate of CpG8 was increased (P<0.05). Multivariate linear regression analysis showed that the decreased methylation rate at the CpG2 site and the increased methylation rate at the CpG8 site were independently associated with elevated SBP and DBP. The linear regression model fitting curves indicated that the increased methylation rate at the CpG2 site was linearly related to the decrease in SBP/DBP (P values for non-linearity were 0.143 and 0.481, respectively), and the increased methylation rate at the CpG8 site was linearly related to the increase in SBP/DBP (P values for non-linearity were 0.727 and 0.940, respectively). Unadjusted Logistic regression analysis showed that the methylation rates of CpG2 and CpG8 were influencing factors of hypertension (P<0.01). Adjusted Logistic regression analysis showed that the increased methylation rate at the CpG2 site was independent protective factors, and the increased methylation rate at the CpG8 site was independent risk factor for hypertension (P<0.01). Conclusion The methylation levels at the CpG2 and CpG8 sites of the Furin promoter are independent factors associated with blood pressure changes in the non - diabetic population in the community.

Key words: hypertension, Furin, promoter regions, genetic, methylation, non-diabetes

CLC Number:

R544.1

Figures/Tables 10

References 24

[1]	BRANT L, PASSAGLIA L G, PINTO-FILHO M M, et al. The burden of resistant hypertension across the world[J]. Curr Hypertens Rep, 2022, 24(3):55-66. doi:10.1007/s11906-022-01173-w.
[2]	DZAU V J, HODGKINSON C P. Precision hypertension[J]. Hypertension, 2024, 81(4):702-708. doi:10.1161/HYPERTENSIONAHA.123.21710.
[3]	RICHARDS E M, LI J, STEVENS B R, et al. Gut microbiome and neuroinflammation in hypertension[J]. Circ Res, 2022, 130(3):401-417. doi:10.1161/CIRCRESAHA.121.319816.
[4]	OZEMEK C, TIWARI S, SABBAHI A, et al. Impact of therapeutic lifestyle changes in resistant hypertension[J]. Prog Cardiovasc Dis, 2020, 63(1):4-9. doi:10.1016/j.pcad.2019.11.012.
[5]	CHAUDHARY M. Novel methylation mark and essential hypertension[J]. J Genet Eng Biotechnol, 2022, 20(1):11. doi:10.1186/s43141-022-00301-y.
[6]	KRESOVICH J K, SANDLER D P, TAYLOR J A. Methylation-based biological age and hypertension prevalence and incidence[J]. Hypertension, 2023, 80(6):1213-1222. doi:10.1161/HYPERTENSIONAHA.122.20796.
[7]	FITZGERALD K. Furin protease:from SARS CoV-2 to anthrax,diabetes,and hypertension[J]. Perm J, 2020, 24:20.187. doi:10.7812/TPP/20.187.
[8]	WICHAIYO S, KOONYOSYING P, MORALES N P. Functional roles of furin in cardio-cerebrovascular diseases[J]. ACS Pharmacol Transl Sci, 2024, 7(3):570-585. doi:10.1021/acsptsci.3c00325.
[9]	PENG H, FAN Y, LI J, et al. DNA methylation of the natriuretic peptide system genes and ischemic stroke:gene-based and gene set analyses[J]. Neurol Genet, 2022, 8(3):e679. doi:10.1212/NXG.0000000000000679.
[10]	HE Y, LI Y, ZHANG J, et al. FURIN promoter methylation predicts the risk of incident diabetes:a prospective analysis in the Gusu cohort[J]. Front Endocrinol(Lausanne), 2022, 13:873012. doi:10.3389/fendo.2022.873012.
[11]	MA S, ZHU J, WU L, et al. FURIN promoter methylation predicts the risk of incident hypertension:a prospective analysis of the Gusu cohort[J]. Cardiology Plus, 2021, 6(1):56. doi:10.4103/2470-7511.312596.
[12]	RUAN Z, LU T, CHEN Y, et al. Association between psoriasis and nonalcoholic fatty liver disease among outpatient US Adults[J]. JAMA Dermatol, 2022, 158(7):745-753. doi:10.1001/jamadermatol.2022.1609.
[13]	GAO H, LI J, MA Q, et al. Causal associations of DNA methylation and cardiovascular disease:a two-sample mendelian randomization study[J]. Glob Heart, 2024, 19(1):48. doi:10.5334/gh.1324.
[14]	WESTERMAN K E, ORDOVÁS J M. DNA methylation and incident cardiovascular disease[J]. Curr Opin Clin Nutr Metab Care, 2020, 23(4):236-240. doi:10.1097/MCO.0000000000000659.
[15]	PRASHER D, GREENWAY S C, SINGH R B. The impact of epigenetics on cardiovascular disease[J]. Biochem Cell Biol, 2020, 98(1):12-22. doi:10.1139/bcb-2019-0045.
[16]	KROLEVETS M, CATE V T, PROCHASKA J H, et al. DNA methylation and cardiovascular disease in humans:a systematic review and database of known CpG methylation sites[J]. Clin Epigenetics, 2023, 15(1):56. doi:10.1186/s13148-023-01468-y.
[17]	DESIDERIO A, PASTORINO M, CAMPITELLI M, et al. DNA methylation in cardiovascular disease and heart failure:novel prediction models?[J]. Clin Epigenetics, 2024, 16(1):115. doi:10.1186/s13148-024-01722-x.
[18]	LI D, LIU X, ZHANG L, et al. COVID-19 disease and malignant cancers:the impact for the furin gene expression in susceptibility to SARS-CoV-2[J]. Int J Biol Sci, 2021, 17(14):3954-3967. doi:10.7150/ijbs.63072.
[19]	YANG W, CAO J, MCVEY D G, et al. Allele-specific epigenetic regulation of FURIN expression at a coronary artery disease susceptibility locus[J]. Cells, 2023, 12(13):1681. doi:10.3390/cells12131681.
[20]	HE Y, REN L, ZHANG Q, et al. Serum furin as a biomarker of high blood pressure:findings from a longitudinal study in Chinese adults[J]. Hypertens Res, 2019, 42(11):1808-1815. doi:10.1038/s41440-019-0295-6.
[21]	HE Y, REN L, ZHANG Q, et al. Deficient serum furin predicts risk of abdominal obesity:findings from a prospective cohort of Chinese adults[J]. Postgrad Med J, 2021, 97(1146):234-238. doi:10.1136/postgradmedj-2019-137422.
[22]	OHWAKI A, NISHIZAWA H, KATO A, et al. Altered serum soluble furin and prorenin receptor levels in pregnancies with pre-eclampsia and fetal growth restriction[J]. J Gynecol Obstet Hum Reprod, 2021, 50(10):102198. doi:10.1016/j.jogoh.2021.102198.
[23]	刘红艳, 杜玉杰, 尤冉冉, 等. H型高血压合并急性心肌梗死患者外周血Furin、sTWEAK、NLR与心肌损伤指标和预后不良的关系[J]. 疑难病杂志, 2023, 22(4):343-349,372.
	LIU H Y, DU Y J, YOU R R, et al. Relationship between peripheral blood Furin,sTWEAK,NLR,myocardial injury markers,and poor prognosis in patients with type H hypertension and acute myocardial infarction[J]. Chin J Diffic and Compl Cas, 2023, 22(4):343-349,372. doi:10.3969/j.issn.1671-6450.2023.04.002.
[24]	FERNANDEZ C, RYSÄ J, ALMGREN P, et al. Plasma levels of the proprotein convertase furin and incidence of diabetes and mortality[J]. J Intern Med, 2018, 284(4):377-387. doi:10.1111/joim.12783.

组别	n	CpG1	CpG2	CpG3	CpG4
SBP正常组	1 388	49.10±6.53	13.12±3.93	62.26±6.03	41.11±5.85
SBP升高组	444	48.37±6.73	11.98±4.16	62.08±5.99	40.19±5.94
t		2.036^＊	5.218^＊＊	0.562	2.890^＊＊
组别		CpG5	CpG6	CpG7	CpG8
SBP正常组		51.70±5.95	35.24±5.75	40.48±5.85	87.23±3.93
SBP升高组		51.65±6.03	34.79±5.87	40.35±5.69	88.25±4.25
t		0.147	1.420	0.409	4.470^＊＊

组别	n	CpG1	CpG2	CpG3	CpG4
SBP正常组	1 388	49.10±6.53	13.12±3.93	62.26±6.03	41.11±5.85
SBP升高组	444	48.37±6.73	11.98±4.16	62.08±5.99	40.19±5.94
t		2.036^＊	5.218^＊＊	0.562	2.890^＊＊
组别		CpG5	CpG6	CpG7	CpG8
SBP正常组		51.70±5.95	35.24±5.75	40.48±5.85	87.23±3.93
SBP升高组		51.65±6.03	34.79±5.87	40.35±5.69	88.25±4.25
t		0.147	1.420	0.409	4.470^＊＊

组别	n	CpG1	CpG2	CpG3	CpG4
DBP正常组	1 341	49.08±6.59	13.12±3.98	62.37±6.06	41.14±5.92
DBP升高组	491	48.48±6.56	12.08±4.02	61.81±5.90	40.20±5.74
t		1.747	4.958^＊＊	1.758	3.060^＊＊
组别		CpG5	CpG6	CpG7	CpG8
DBP正常组		51.70±6.03	35.29±5.84	40.42±5.84	87.17±3.94
DBP升高组		51.66±5.79	34.71±5.61	40.55±5.75	88.33±4.16
t		0.114	1.888	0.418	5.518^＊＊

组别	n	CpG1	CpG2	CpG3	CpG4
DBP正常组	1 341	49.08±6.59	13.12±3.98	62.37±6.06	41.14±5.92
DBP升高组	491	48.48±6.56	12.08±4.02	61.81±5.90	40.20±5.74
t		1.747	4.958^＊＊	1.758	3.060^＊＊
组别		CpG5	CpG6	CpG7	CpG8
DBP正常组		51.70±6.03	35.29±5.84	40.42±5.84	87.17±3.94
DBP升高组		51.66±5.79	34.71±5.61	40.55±5.75	88.33±4.16
t		0.114	1.888	0.418	5.518^＊＊

组别	n	CpG1	CpG2	CpG3	CpG4
血压正常组	1 218	49.15±6.59	13.23±3.94	62.37±6.02	41.20±5.92
高血压组	614	48.47±6.55	12.07±4.06	61.91±6.02	40.27±5.78
t		2.081^＊	5.870^＊＊	1.527	3.199^＊＊
组别		CpG5	CpG6	CpG7	CpG8
血压正常组		51.75±6.01	35.32±5.79	40.44±5.87	87.09±3.91
高血压组		51.57±5.89	34.75±5.75	40.48±5.70	88.24±4.15
t		0.597	1.999^＊	0.123	5.821^＊＊